<DOC>
	<DOCNO>NCT00990860</DOCNO>
	<brief_summary>TACE possibly play significant role contribute subgroup survive residual tumor tissue characterize aggressive biology . This explain strong scientific rationale explore role anti-angiogenic therapy sorafenib remedy strengthen therapeutic efficacy TACE combat liver cancer . Sorafenib play prominent auxiliary role suppress tumor growth prolong time recurrence progression . Performing TACE sorafenib administration may synergic effect hepatic tumoral lesion .</brief_summary>
	<brief_title>Study Asia Combination TACE With Sorafenib HCC Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age ≧ 18 life expectancy &gt; 12 week Histologically diagnose HCC , OR clinically diagnose HCC patient difficulty obtain histological diagnosis . A clinically diagnose HCC fulfill ALL criterion Chronic hepatitis B C and/or evidence liver cirrhosis . Presence hepatic tumour ( ) image finding compatible HCC , evidence gastrointestinal tumours A persistent elevation serum AFP &gt; = 400 ng/ml without evidence exist αfetoproteinsecreting germ cell tumour ChildPugh score ≦ 7 BCLC B The patient must solitary hepatic tumour great 3 cm diameter multifocal disease evidence CT MRI scan . The target lesion must previously treat local therapy The patient must candidate surgical resection ablation tumour . Size large tumor ≦10cm large dimension Patients receive previous local therapy treatment ( RFA , PEI , cryoablation , surgery , resection ) nontarget lesion eligible Local therapy must complete least 4 week prior baseline scan . ECOG performance status 0 1 Hb ≧ 9g/dL , Absolute neutrophil count &gt; 1000/mm3 Platelet count ≧ 60x109/L Adequate clot function : INR &lt; 1.5 Hepatic : AST ALT &lt; 5 X ULN Renal : serum creatinine &lt; 1.5 x ULN Bilirubin ≦ 3mg/dL The patient must give write , informed consent Tumor factor Presence extrahepatic metastasis Predominantly infiltrative lesion Diffuse tumor morphology extensive lesion involve lobe . Vascular complication Hepatic artery thrombosis , Partial complete thrombosis main portal vein , Tumor invasion portal branch contralateral lobe , Hepatic vein tumor thrombus , Significant arterioportal shunt amenable shunt blockage Liver function Advanced liver disease : ascites , hepatic encephalopathy Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . Others Pregnant lactating woman . Active sepsis bleeding . Hypersensitivity intravenous contrast agent . The patient receive prior treatment HCC target lesion . History cardiac disease Congestive heart failure &gt; NYHA class 2 ; active coronary artery disease Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management . Therapeutic anticoagulation coumarin , heparin , heparinoids . Serious nonhealing wound ( include wound heal secondary intention ) , acute nonhealing ulcer , bone fracture within 3 month . Impairment swallow would preclude administration sorafenib . The patient , opinion investigator , unable / unwilling comply treatment study instruction . Previous concurrent cancer distinct primary site histology HCC , EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat &gt; 3 year prior entry permit Any active clinically serious infection ( &gt; grade 2 NCICTCAE ver 3.0 ) HIV infection AIDSrelated illness serious acute chronic illness ( base medical history )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Combination TACE With Sorafenib</keyword>
</DOC>